Esperion misses revenue estimate. Another lackluster net revenue. 66 million in net losses.

Quote






anonymous said:
To top it off 13.4 million in product revenue. Very flat sales. No growth to speak of. This wasn't a good report.
Click to expand...

Yes, it's terrible, though the stock price hasn't done much in response. Last year, I thought ESPR was headed toward a reverse merger, but with public markets tanking, I'm now leaning towards Chapter 11. Unfortunately, the company will continue to survive for a while longer.
 


















He also was a failure at Sanofi. The finance articles all reported that Esperion missed its revenue and earnings and that sales results were dismal. Not very good. I would think anything is on the table now including Chapter 11.
 






anonymous said:
He also was a failure at Sanofi. The finance articles all reported that Esperion missed its revenue and earnings and that sales results were dismal. Not very good. I would think anything is on the table now including Chapter 11.
Click to expand...

He was certainly an interesting choice, to be kind, nothing in his past suggested he would do anything other than run Esperion into the ground, and well, here we are.
 






Where is Mr. Sunshine since the earnings....hmm lack of earnings call ?

What new adjectives will he have to prop up ESPR ?

Pivot, Leg up, circle back, rocket, bio-tech, leg up, cup and handle have not worked.
 






This was another bad earnings call. It's not good when you missing revenue and earnings estimates. What will be the plan moving forward? Will Esperion survive in time for their coveted landmark trial ???? Is the trial going to make a difference in this already selling space. Will the generic statin like reductions make a difference. The board has been completely useless.
 






anonymous said:
This was another bad earnings call. It's not good when you missing revenue and earnings estimates. What will be the plan moving forward? Will Esperion survive in time for their coveted landmark trial ???? Is the trial going to make a difference in this already selling space. Will the generic statin like reductions make a difference. The board has been completely useless.
Click to expand...

Exactly.
And wouldn't you know Esperion has expanded the Board !

Soon the Board will out number the Scientific Hired, Highly Tenured Customer Facing Team and Lipid Trained Experts !
 






That's a totally shitty business plane to have more board members than reps. That idiot Eric is by far the most clueless of the bunch. Where don't hey fond these pharma rejects?
 






A bunch of us moved on quickly after a few months at the start. You could see management had no idea what they were doing. The ones who really stood out for incompetence were the regional directors. They were nothing more than a district manager but loved being called Regional Directors. What a laugh! This pretty much played out like everyone thought on the company's current state.
 






anonymous said:
That's a totally shitty business plane to have more board members than reps. That idiot Eric is by far the most clueless of the bunch. Where don't hey fond these pharma rejects?
Click to expand...
Well folks, the stock is only up about 20% year to date, and the floor is in. Look for some fairly pronounced activity over the next six weeks you’re gonna see a push to seven.Big Pharma has been punished recently due to the pending legislation, and now that that appears to be resolved in a somewhat favorable manner you’ll see some strong price action.
 
















































So if you didn’t make the cut, which you didn’t, what does that say about you? Your resilience is apparently nonexistent as it’s been ALMOST 3 YEARS since you stunk up the interview. What a loser.
 






Top Bottom
Back
Quote